PL2603503T3 - Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania - Google Patents

Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania

Info

Publication number
PL2603503T3
PL2603503T3 PL11764455T PL11764455T PL2603503T3 PL 2603503 T3 PL2603503 T3 PL 2603503T3 PL 11764455 T PL11764455 T PL 11764455T PL 11764455 T PL11764455 T PL 11764455T PL 2603503 T3 PL2603503 T3 PL 2603503T3
Authority
PL
Poland
Prior art keywords
preparation
solid state
state forms
dabigatran etexilate
bismesylate salt
Prior art date
Application number
PL11764455T
Other languages
English (en)
Inventor
Dirk Fischer
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of PL2603503T3 publication Critical patent/PL2603503T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11764455T 2010-09-27 2011-09-27 Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania PL2603503T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10179845 2010-09-27
US41702210P 2010-11-24 2010-11-24
PCT/US2011/053381 WO2012044595A1 (en) 2010-09-27 2011-09-27 Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
EP11764455.9A EP2603503B1 (en) 2010-09-27 2011-09-27 Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof

Publications (1)

Publication Number Publication Date
PL2603503T3 true PL2603503T3 (pl) 2015-12-31

Family

ID=44736109

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11764455T PL2603503T3 (pl) 2010-09-27 2011-09-27 Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania

Country Status (5)

Country Link
EP (1) EP2603503B1 (pl)
ES (1) ES2550771T3 (pl)
HU (1) HUE026408T2 (pl)
PL (1) PL2603503T3 (pl)
WO (1) WO2012044595A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
EP2900652A2 (en) 2012-09-28 2015-08-05 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014049585A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014178017A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
WO2015033353A2 (en) * 2013-09-03 2015-03-12 Laurus Labs Private Limited Novel acid addition salts of dabigatran etexilate and process for the preparation thereof
EP2853260A1 (en) * 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015124764A1 (en) 2014-02-24 2015-08-27 Erregierre S.P.A. Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate
CN104892574A (zh) 2014-03-04 2015-09-09 浙江海正药业股份有限公司 达比加群酯甲磺酸盐的晶型及其制备方法和用途
US20170165247A1 (en) * 2014-07-18 2017-06-15 Olon S.P.A. Crystalline compounds of dabigatran etexilate
WO2016020471A1 (en) * 2014-08-07 2016-02-11 Boehringer Ingelheim International Gmbh Method for producing dabigatran etexilate methanesulphonate
KR102147600B1 (ko) * 2019-04-15 2020-08-25 유니셀랩 주식회사 신규한 다비가트란 에텍실레이트 헤미에데실레이트의 다형체 및, 이의 제조방법
CN113933400B (zh) * 2020-06-29 2024-01-12 石药集团恩必普药业有限公司 一种达比加群酯原料药或制剂中基因毒性杂质的检测方法
CN114113346B (zh) * 2020-08-25 2024-01-12 石药集团恩必普药业有限公司 一种达比加群酯原料药或制剂中对甲苯磺酸乙酯、对甲苯磺酸异丙酯的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
CA2476054C (en) 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
EP1609784A1 (de) 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
US20100087488A1 (en) 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
EP2603503A1 (en) 2013-06-19
EP2603503B1 (en) 2015-08-05
ES2550771T3 (es) 2015-11-12
HUE026408T2 (en) 2016-06-28
WO2012044595A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
PL2603503T3 (pl) Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania
IL227648A0 (en) Process for preparing 4-amino-5-fluoro-3-halo-6-(converted) picolinates
ZA201307225B (en) Methods for genomic modification
SI3412687T1 (sl) Postopek zdravljenja DLBCL
EP2640190A4 (en) MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
IL227646A0 (en) Process for preparing 4-amino-3-chloro-5-fluoro-6-(converted) picolinates
ZA201305582B (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(sunstituted)picolinates
PT3616695T (pt) Ceftolozano/tazobactam para tratar infeções intrapulmonares
ZA201500701B (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates
IL227645B (en) Process for preparing 4-amino-3-chloro-5-fluoro-6-(converted) picolinates
ZA201504166B (en) Process for the preparation of 4-amino-5-fluoro-3-chloro-6-(substituted)picolinates
ZA201207397B (en) Process for the preparation of dexlansoprazole
IL227544B (en) (r)- Leoplomide, a method for its preparation and its medical uses
ZA201205320B (en) Preparation process of the sodium salt of esomeprazole
ZA201504165B (en) Process for the preparation of 4-amino-5-fluoro-3-chloro-6-(substituted)picolinates
ZA201303872B (en) Improved process for the preparation of 2-trifluoromethyl-5-(1-substituted)alkylpyridines
IL239228A0 (en) Improved process for the preparation of n-cyano-s-[1-(pyridine-3-yl)ethyl]-s-methylsulfylamines
IL232630A0 (en) A method for the preparation of 6,2-difluoroacetophenones
EP2793871A4 (en) COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND / OR ABLATION
ZA201309732B (en) Process for the preparation of dexlansoprazole
GB201107995D0 (en) Cytotoxic pyridyl compounds